메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Sciwind Biosciences Published T2DM Phase III EECOH-1 Trial Results of Ecnoglutide in Nature Communications

HANGZHOU, China, Jan. 28, 2026 -- Recently, the results of the pivotal Phase III clinical trial (EECOH-1) of ecnoglutide injection, developed by Sciwind Biosciences Co., Ltd. ("Sciwind"), for the monotherapy of type 2 diabetes (T2DM), have been published in Nature Communications. Conducted in adult T2DM patients with inadequate glycemic control after diet and exercise intervention, the results demonstrate that ecnoglutide injection — potentially the world's first long-acting cAMP-biased GLP-1 receptor agonist — significantly lowers blood glucose while also showing comprehensive bene
- 김갑성 기자
- 2026-01-28 19:39
CHCC 2026 Opens Registration, Offering a One-Stop Platform for Hospital Construction Solutions and Real-World Applications

TIANJIN, China, Jan. 28, 2026 -- The 27th China Hospital Construction Conference & International Hospital Build and Infrastructure Exposition (CHCC 2026), a globally recognized hospital construction event, will be held from May 23 to 25, 2026, at the National Convention and Exhibition Center (Tianjin), China. Having been held successfully for 26 consecutive editions, CHCC has evolved into a widely recognized industry platform in the hospital construction sector, bringing together academic insights and industry practice. The event offers a one-stop platform for healthcare infrastruc
- 김갑성 기자
- 2026-01-28 15:01
Hanmi Secures Export Deal with Mexican Partner Sanfer for GLP-1 Obesity Drug and More

Hanmi Signs Exclusive Partnership with New Mexican Partner Laboratorios Sanfer, Covering Efpeglenatide and Diabetes Treatments SEOUL, South Korea, Jan. 28, 2026 -- Hanmi is accelerating its global market entry with efpeglenatide, Korea's first domestically developed GLP-1 class obesity and metabolic disease treatment. Hanmi Pharmaceutical, the core operating company of Hanmi Science, announced on January 28 that it has signed an exclusive distribution agreement with Mexican pharmaceutical company Laboratorios Sanfer for efpeglenatide, its GLP-1 obesity the
- 김갑성 기자
- 2026-01-28 12:08
US FDA Approves First Daily Oral GLP‑1 Treatment for Weight Management, Showing Comparable Results to Injectable Therapy

[ 메디채널 김갑성 기자 ] The US Food and Drug Administration (FDA) has approved Novo Nordisk's new once-daily pill for weight management, designed to help people reduce excess body weight and maintain weight reduction over the long term. In clinical trials, patients achieved an average weight reduction of 16.6% from baseline. The therapy is also indicated to lower the risk of major cardiovascular events* such as heart attack and stroke in certain patients. Novo Nordisk expects to launch the pill in the United States in early January 2026. JAKARTA, Indonesia, Jan. 28, 2026 -- [ 메디채널 김갑성 기자 ]
- 김갑성 기자
- 2026-01-28 10:45
Singapore Eye Research Institute tops ScholarGPS rankings in Ophthalmology

The Institute has placed #1 in ophthalmology among all non-academic institutes, and #2 in the same field among all institutes, globally. SINGAPORE, Jan. 28, 2026 -- The Singapore Eye Research Institute (SERI) has achieved a landmark milestone in December 2025 by securing first place among all non-academic institutes in ophthalmology, on the American scholarly analytics platform ScholarGPS, whilst also claiming second place overall among all institutes in the field globally. This is based on data from the last five years evaluated by the platform. The a
- 김갑성 기자
- 2026-01-28 10:00
Organizations Without AI Security Policies Are Already Behind, Warns Armor

Armor releases AI governance framework to address critical policy gap as enterprise AI adoption accelerates DALLAS, Jan. 28, 2026 -- Armor, a leading provider of cloud-native managed detection and response (MDR) services protecting more than 1,700 organizations across 40 countries, today issued guidance to enterprises: Organizations deploying artificial intelligence tools without formal governance policies are creating avoidable blind spots in their security posture and exposing themselves to data loss, compliance violations, and emerging AI-specific threats. "If yo
- 김갑성 기자
- 2026-01-28 02:21
Asthma and Allergy Drug Development Is Failing Too Often--A Translational Reset Is Needed: HKEY-AIRx™1.0

BOSTON and SUZHOU, China, Jan. 27, 2026 -- HKeyBio, a preclinical CRO focused on autoimmune and allergic disease drug development, today announced a translational preclinical strategy, HKEY-AIRxTM1.0 designed to address one of the most persistent problems facing biotech leadership: why so many asthma and allergy programs with strong preclinical data fail to deliver meaningful clinical outcomes. Over the past decade, asthma and allergic airway diseases have attracted substantial investment, the emergence of advanced biologics, and increasingly sophisticated targets. Yet for biotech and
- 김갑성 기자
- 2026-01-27 22:00
Insilico Medicine and Qilu Pharmaceutical Reach Near $120 Million Drug Development Collaboration to Accelerate Novel Cardiometabolic Therapies

CAMBRIDGE, Mass., Jan. 27, 2026 -- Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, and Qilu Pharmaceutical Group, a major comprehensive modern pharmaceutical enterprise in China, as well as its subsidiary Shanghai Qilu Pharmaceutical Research Center, today announced a strategic partnership on innovative drug development, leveraging Insilico's proprietary Pharma.AI platform to jointly develop small molecule inhibitors, focusing on specific targets for cardiometabolic disease management. According to the agreement, Insilico Medicine will utilize its pr
- 김갑성 기자
- 2026-01-27 22:00
Home Control Signs Memorandum of Understanding with NTU Singapore to Explore AIoT Home Healthcare Ecosystem

HONG KONG, Jan. 27, 2026 -- Home Control International Limited ("Home Control" or the "Company", together with its subsidiaries, the "Group"; Stock Code: 1747.HK) is pleased to announce that it has entered into a Strategic Memorandum of Understanding (MoU) with Nanyang Technological University, Singapore ("NTU Singapore"). The parties will negotiate and explore the possibility of cooperation and collaboration on Artificial Intelligence of Things ("AIoT") enabled home healthcare solutions, marking a significant milestone in the Group's strategi
- 김갑성 기자
- 2026-01-27 21:25
Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease

Nine-month findings show mean improvement in Composite Unified Huntington's Disease Rating Scale from baseline of +0.64 points, compared to natural history expected worsening of cUHDRS in symptomatic patients of -0.73 points over nine months, based on propensity score weighting. Skyhawk also announces SKY-0515's Phase 2/3 FALCON-HD trial has expanded worldwide. Skyhawk has now dosed more than 90 patients. BOSTON, Jan. 27, 2026 -- Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies to modulate critical RNA targets,
- 김갑성 기자
- 2026-01-27 21:00

이전

21 22 23 24 25 26 27 28 29 30

많이 본 기사

최근기사

2026-03-03_TUE

2026-03-02_MON

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 03월 03일 03시 40분